Results: 69/135 (51, 1%) of NSCLC patients have mutation in exon 19, 20 and 21 of EGFR gene; 9/135 (6, 7%) of NSCLC patients have EML4-ALK rearrangement mutation and 3/135 (2, 2%) of NSCLC patients have ROS1 rearrangement mutation.